Considering the availability of FISH genetic testing, and potential therapeutic roles in the presence of FGFR2 resistance mutations or the possibility of coadministration with CYP3A inhibitors/inducers, tasurgratinib has practical applications and may be a beneficial future addition to current treatment paradigms for CCA with FGFR2 fusions or rearrangements. Here, FGFR2 is linked to cholangiocarcinoma.